(Legal Newsline) — The U.S. Federal Trade Commission (FTC) announced Feb. 24
that, following a public comment period, it has approved a final order settling
charges that Boehringer Ingelheim’s $13.53 billion asset swap with
Paris-based Sanofi would likely be anti-competitive.
The FTC had
alleged that without a settlement, the swap would have harmed U.S. market
competition for different products, including vaccines for companion animals, or
pets, and select parasite control products for cattle and sheep.
final order, Boehringer Ingelheim will divest select canine, feline and rabies
vaccines to Eli Lilly and Company and its Elanco animal health division.
Additionally, Boehringer Ingelheim must divest to Bayer AG select parasite control products.
voted 3-0 to approve the final order. The staff contact for the case is Michael
Barnett of the Bureau of Competition.